The role of Souvenaid® in the management of patients with early Alzheimer’s disease including mild cognitive impairment.

September 2024 ･ 7 min watch

Link copied!

For the management of patients with early Alzheimer’s disease.

Key takeaways

  • Souvenaid ® is clinically proven to slow the progression of memory and cognitive decline by 60% over a 3 year period in an early stage of Alzheimers disease (AD) known as mild cognitive impairment (MCI).1
  • Clinical data indicates that Souvenaid ® use reduced brain atrophy by 33% over a 3 year period in an early stage of AD known as MCI.1
  • In MCI due to AD, the time component test (TCT) metric may help to assess the meaningfulness of research outcomes, including those from the LipiDiDiet randomized controlled trial (RCT).
  • A gTCT combined analysis of the 2 year data set from the LipiDiDiet RCT, showed that Fortasyn® Connect (Souvenaid®) slowed disease progression by 9 months in people with MCI due to AD.2
  • There are Australian nationally informed guidelines on the detection, assessment and management of MCI available. These recommendations include lifestyle interventions such as physical activity, nutrition, Souvenaid ®, cognitive activity, social connection and mindfulness.3
  • These nationally informed MCI recommendations state that patients with MCI should be informed of the 3 year LipiDiDiet RCT and the availability of Souvenaid®in Australia. 3
  • Clinical research has found Souvenaid®to be well tolerated and have a positive safety profile.1,4,5

In this 7 minute lecture, Associate Professor Michael Woodward discusses the evidence for the medical food Souvenaid® and its role in the management of patients with early Alzheimer’s disease including mild cognitive impairment.

Was this helpful?
0 0
  1. Soininen H, et al. Alzheimer’s Dement 2021;17:29–40
  2. Dickson et al. J Prev Alzheimer’s Dis 2024; 11(4):992-997
  3. Woodward M, et al. J of Alzheimer’s Dis 2022; 89 803-809
  4. Scheltens P, et al. Alzheimer’s Dement 2010; 6: 1–10.e1
  5. Scheltens P, et al. J Alzheimer’s Dis 2012; 31: 225–236